The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis
Abstract
BACKGROUND: Urinary biomarkers may be a useful alternative or adjunct to cystoscopy for diagnosis of bladder cancer. PURPOSE: To systematically review the evidence on the accuracy of urinary biomarkers for diagnosis of bladder cancer in adults who have signs or symptoms of the disease or are undergoing surveillance for recurrent disease. DATA SOURCES: Ovid MEDLINE (January 1990 through June 2015), Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and reference lists. STUDY SELECTION: 57 studies that evaluated the diagnostic accuracy of quantitative or qualitative nuclear matrix protein 22 (NMP22), qualitative or quantitative bladder tumor antigen (BTA), fluorescence in situ hybridization (FISH), fluorescent immunohistochemistry (ImmunoCyt [Scimedx]), and Cxbladder (Pacific Edge Diagnostics USA) using cystoscopy and histopathology as the reference standard met inclusion criteria. Case-control studies were excluded. DATA EXTRACTION: Dual extraction and quality assessment of individual studies. Overall strength of evidence (SOE) was also assessed. DATA SYNTHESIS: Across biomarkers, sensitivities ranged from 0.57 to 0.82 and specificities ranged from 0.74 to 0.88. Positive likelihood ratios ranged from 2.52 to 5.53, and negative likelihood ratios ranged from 0.21 to 0.48 (moderate SOE for quantitative NMP22, qualitative BTA, FISH, and ImmunoCyt; low SOE for others). For some biomarkers, sensitivity was higher for initial diagnosis of bladder cancer than for diagnosis of recurrence. Sensitivity increased with higher tumor stage or grade. Studies that directly compared the accuracy of quantitative NMP22 and qualitative BTA found no differences in diagnostic accuracy (moderate SOE); head-to-head studies of other biomarkers were limited. Urinary biomarkers plus cytologic evaluation were more sensitive than biomarkers alone but missed about 10% of bladder cancer cases. LIMITATION: Restricted to English-language studies; no search for studies published only as abstracts; statistical heterogeneity present in most analyses; few studies for qualitative NMP22, quantitative BTA, and Cxbladder; and methodological shortcomings in almost all studies. CONCLUSION: Urinary biomarkers miss a substantial proportion of patients with bladder cancer and are subject to false-positive results in others. Accuracy is poor for low-stage and low-grade tumors. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality. (PROSPERO registration number: CRD42014013284).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Empirical evidence of design-related bias in studies of diagnostic tests.
Lijmer, J. G. (1999) · JAMA · doi:10.1001/jama.282.11.1061 · Cited by 1,861
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W. G., Compérat, E., Sylvester, R. J., Kaasinen, E., Böhle, A., Palou Redorta, J., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.06.003 · Cited by 1,174
Hall, M. C., Chang, S. S., Dalbagni, G., Pruthi, R. S., Seigne, J. D., Skinner, E. C., Wolf, J. S., & Schellhammer, P. F. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.09.003 · Cited by 830
Chu, H., & Cole, S. R. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.06.011 · Cited by 708
PROSPERO: an international prospective register of systematic reviews
Wright, K. E. (2014) · Cited by 568
Urine Markers for Bladder Cancer Surveillance: A Systematic Review
van Rhijn, B. W. G., van der Poel, H. G., & van der Kwast, T. H. (2005) · European Urology · doi:10.1016/j.eururo.2005.03.014 · Cited by 530
Lotan, Y., & Roehrborn, C. G. (2003) · Urology · doi:10.1016/s0090-4295(02)02136-2 · Cited by 474
Exploring sources of heterogeneity in systematic reviews of diagnostic tests
Lijmer, J. G., Bossuyt, P. M. M., & Heisterkamp, S. H. (2002) · Statistics in Medicine · doi:10.1002/sim.1185 · Cited by 446
Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay
Grossman, H. B. (2005) · JAMA · doi:10.1001/jama.293.7.810 · Cited by 367
Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic Assay
Grossman, H. B. (2006) · JAMA · doi:10.1001/jama.295.3.299 · Cited by 265
Hajdinjak, T. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.06.002 · Cited by 244
Meta-Analysis of Diagnostic and Screening Test Accuracy Evaluations: Methodologic Primer
Gatsonis, C., & Paliwal, P. (2006) · American Journal of Roentgenology · doi:10.2214/ajr.06.0226 · Cited by 215
We should not pool diagnostic likelihood ratios in systematic reviews
Zwinderman, A. H., & Bossuyt, P. M. (2008) · Statistics in Medicine · doi:10.1002/sim.2992 · Cited by 205
SHARMA, S., ZIPPE, C. D., PANDRANGI, L., NELSON, D., & AGARWAL, A. (1999) · Journal of Urology · doi:10.1097/00005392-199907000-00014 · Cited by 194
HALLING, K. C., KING, W., SOKOLOVA, I. A., KARNES, R. J., MEYER, R. G., POWELL, E. L., SEBO, T. J., CHEVILLE, J. C., CLAYTON, A. C., KRAJNIK, K. L., et al. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)65072-0 · Cited by 188
Empirical evidence of the importance of comparative studies of diagnostic test accuracy
Takwoingi, Y., Leeflang, M. M. G., & Deeks, J. J. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-7-201304020-00006 · Cited by 187
A study comparing various noninvasive methods of detecting bladder cancer in urine
Saad, A., Hanbury, D. C., McNicholas, T., Boustead, G. B., Morgan, S., & Woodman, A. (2002) · British Journal of Urology · doi:10.1046/j.1464-4096.2001.01699.x · Cited by 117
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer
Lotan, Y., Shariat, S. F., Schmitz‐Dräger, B. J., Sänchez‐Carbayo, M., Jankevičius, F., Racioppi, M., Minner, S. J. P., Stöhr, B., Bassi, P. F., & Grossman, H. B. (2010) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.11.004 · Cited by 105
Chapter 8: Meta-analysis of Test Performance When There is a “Gold Standard”
Trikalinos, T. A., Balion, C. M., Coleman, C. I., Griffith, L. E., Santaguida, P. L., Vandermeer, B., & Fu, R. F. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2029-1 · Cited by 104
Self-citationTêtu, B., Tiguert, R., Harel, F., & Fradet, Y. (2004) · Modern Pathology · doi:10.1038/modpathol.3800262 · Cited by 101
Giannopoulos, A., MANOUSAKAS, T., GOUNARI, A., et al. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65965-4 · Cited by 85
When are summary ROC curves appropriate for diagnostic meta‐analyses?
Chappell, F. M., RAAB, G. M., & Wardlaw, J. M. (2009) · Statistics in Medicine · doi:10.1002/sim.3631 · Cited by 81
Cha, E. K., Tirsar, L.-A., Schwentner, C., Christos, P. J., Mian, C., Hennenlotter, J., Martini, T., Stenzl, A., Pycha, A., Shariat, S. F., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.08.073 · Cited by 51
Biomarkers for prognosis and treatment selection in advanced bladder cancer patients
Ru, Y., Dancik, G. M., & Theodorescu, D. (2011) · Current Opinion in Urology · doi:10.1097/mou.0b013e32834956d6 · Cited by 51
Raitanen, M., Leppilahti, M., Tuhkanen, K., et al. (2001) · PubMed · Cited by 31
Chahal, R., Darshane, A., Browning, A., et al. (2001) · European Urology · doi:10.1159/000049809 · Cited by 26
Raitanen, M., m, P. H. O., Marttila, T. I., Korhonen, H., Talja, M. T., Ervasti, J., & Tammela, T. L. J. (2001) · European Urology · doi:10.1159/000049810 · Cited by 21
Paoluzzi, M., Mg, C., Mugnaini, P., et al. (1999) · PubMed · Cited by 18
Cited by
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Kamat, A. M., Hahn, N. M., Efstathiou, J. A., Lerner, S. P., Malmström, P.-U., Choi, W., Guo, C. C., Lotan, Y., & Kassouf, W. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30512-8 · Cited by 1,421
Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values
Dhama, K., Latheef, S. K., Dadar, M., Samad, H. A., Munjal, A., Khandia, R., Karthik, K., Tiwari, R., Yatoo, M. I., Bhatt, P., et al. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00091 · Cited by 321
Circulating miRNA panels for specific and early detection in bladder cancer
Usuba, W., Urabe, F., Yamamoto, Y., Matsuzaki, J., Sasaki, H., Ichikawa, M., Takizawa, S., Aoki, Y., Niida, S., Kato, K., et al. (2019) · Cancer Science · doi:10.1111/cas.13856 · Cited by 257
Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
Dudley, J. C., Schroers-Martin, J., Lazzareschi, D. V., Shi, W. Y., Chen, S. B., Esfahani, M. S., Trivedi, D., Chabon, J. J., Chaudhuri, A. A., Stehr, H., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0825 · Cited by 253
Metadata
- Authors
- Chou, R., Gore, J. L., Buckley, D., Fu, R., Gustafson, K., Griffin, J. C., Grusing, S., & Selph, S.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2015-12-15
- Volume
- 163
- Issue
- 12
- Pages
- 922-931
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2209095244
- Cited by
- 267
- References
- 31
- FWCI
- 18.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.